MACK vs. RIGL, VSTM, VNDA, RGLS, XOMA, EBS, LXRX, OPK, OVID, and GALT
Should you be buying Merrimack Pharmaceuticals stock or one of its competitors? The main competitors of Merrimack Pharmaceuticals include Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Regulus Therapeutics (RGLS), XOMA (XOMA), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), Ovid Therapeutics (OVID), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Merrimack Pharmaceuticals (NASDAQ:MACK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 64.0% of Merrimack Pharmaceuticals shares are held by institutional investors. 9.0% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 28.9% of Merrimack Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Merrimack Pharmaceuticals has a net margin of 0.00% compared to Merrimack Pharmaceuticals' net margin of -21.47%. Merrimack Pharmaceuticals' return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
Merrimack Pharmaceuticals has lower revenue, but higher earnings than Rigel Pharmaceuticals. Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rigel Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.
In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 1 mentions for Merrimack Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.00 beat Merrimack Pharmaceuticals' score of -0.33 indicating that Merrimack Pharmaceuticals is being referred to more favorably in the news media.
Rigel Pharmaceuticals received 50 more outperform votes than Merrimack Pharmaceuticals when rated by MarketBeat users. Likewise, 68.81% of users gave Rigel Pharmaceuticals an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.
Rigel Pharmaceuticals presently has a consensus price target of $5.81, suggesting a potential upside of 384.38%. Given Merrimack Pharmaceuticals' higher possible upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Merrimack Pharmaceuticals.
Summary
Rigel Pharmaceuticals beats Merrimack Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Merrimack Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Merrimack Pharmaceuticals Competitors List
Related Companies and Tools
